Takeda, IDT help manufacture Janssen COVID-19 vaccine

By The Science Advisory Board staff writers

March 15, 2021 -- Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.

Takeda will make manufacturing capacity available at IDT's facilities in Germany and Japan. After three months, the capacity will be returned to Takeda to resume manufacturing for the planned launch of its dengue vaccine, TAK-003, subject to regulatory approvals.

Takeda previously announced that it is partnering with Novavax and Moderna to manufacture and distribute the authorized vaccines in Japan.

Copyright © 2021 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here